POSTER SESSION V Wednesday, March 2, 2005   —  9:30 AM - 12:00 Noon Convention Center, Exhibit Hall B GENITOURINARY PATHOLOGY 76 Biochemical Recurrence of Patients with Pathologically Organ-Confined Prostate Cancer (pT2) after Radical Prostatectomy: Analysis of Patients Demographics, Pre-Op PSA and Tumor Parameters in a Cohort of 872 pT2 Patients (726) V Pansare, A Andea, K Kolizeras, M Che, D Grignon, W Sakr - Harper University Hospital, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Medical University of South Carolina, Charleston, SC 77 Relationship of Age to Outcome and Clinicopathologic Findings in Men Submitted to Radical Prostatectomy (594) A Billis, LA Magna, MMM Lira, LR Moreira, H Okamura, AR Paz, RC Perina, RM Triglia, U Ferreira - School of Medicine, State University of Campinas (UNICAMP), Campinas, Sno Paulo, Brazil 78 Characteristics of Metastatic Prostate Cancer (607) M Che, RS Singh, W Sakr, D Grignon - Wayne State University, Detroit, MI 79 The Utility of Pathology Parameters To Predict Prostate Cancer Specific Death: A Population-Based Study in Sweden (580) O Andren, TA Bismar, K Fall, S-O Andersson, J-E Johansson, MA Rubin - Örebro University Hospital, Örebro, Sweden; Brigham and Women's Hospital, Boston, MA; Karolinska Institute, Stockholm, Sweden 80 Relationship between Prostate Cancer and Tuberculosis in the Inhabitants of the Semipalatinsk Region in Kazakhstan (736) MY Pruglo, TM Wheeler, GE Ayala - Baylor College of Medicine, Houston, TX; State Medical Academy, Semipalatinsk, Kazakhstan 81 Ethnic Peculiarities of Latent Cancer of Prostate of the Inhabitants around Former Semipalatinsk Nuclear Test Site (Kazakhstan) (737) MY Pruglo, TM Wheeler, GE Ayala - Baylor College of Medicine, Houston, TX; State Medical Academy, Semipalatinsk, Kazakhstan 82 Cancerous and Precancerous Processes in Prostates of the Inhabitants of Semipalatinsk Region (East Kazakhstan) (795) TM Wheeler, MY Pruglo, GE Ayala - Baylor College of Medicine, Houston, TX; State Medical Academy, Semipalatinsk, Kazakhstan 83 Serum PSA Level Correlates with the Needle Biopsy Extent of Atrophy and Chronic Inflammation, but Not with High Grade Pin and Prostate Cancer (712) C Magi-Galluzzi, L Schoenfield, E Klein, S Jones, M Zhou - Cleveland Clinic Foundation, Cleveland, OH 84 Visual Estimation of Tumor Extent Is Not an Independent Predictor of PSA Recurrence (686) TD Jones, MO Koch, H Lin, L Cheng - Indiana University, Indianapolis, IN; Indiana University, Indianapolis, IN; Yale University, New Haven, CT 85 Reactive Stroma in Needle Biopsies Predicts Biochemical Recurrence-Free Survival in Patients after Radical Prostatectomy (800) N Yanagisawa, G Ayala, R Li, TM Wheeler - Baylor College of Medicine, Houston, TX 86 Prostate Cancer (Ca) c-Myc (8q24) Amplification Detected by Fluorescence In Situ Hybridization (FISH) and MIB-I Proliferation in Needle Biopsy (NBx) Predict Risk of Clinical Progression after Radical Prostatectomy (RP) (753) TJ Sebo, CD Dora, F Lan, Y Kondo, JM Slezak, EJ Bergstralh, RB Jenkins - Mayo Clinic, Rochester, MN 87 Epidermal Growth Factor Receptor (ErbB1) Expression in Prostate Cancer Progression: Correlation with Androgen Independence (754) RB Shah, D Ghosh, K Pienta, JT Elder - University of Michigan, Ann Arbor, MI 88 Heterogeneous Androgen Receptor (AR) Protein Expression in Metastatic Androgen-Independent Prostate Cancer: Implications for Complex AR Mechanisms in the Progression to Androgen Independent Prostate Cancer (755) RB Shah, A Chinnaiyan, R Mehra, S Varambally, R Shen, J Harwood, T Bismar, R Kim, K Pienta, MA Rubin - University of Michigan, Ann Arbor, MI; Brigham and Women's Hospital, Boston, MI 89 Sensitive Detection of Small Focal Cancer on Prostate Needle Biopsy by a-Methylacyl-CoA Racemase (AMACR)/P504S Envision Immunohistochemistry (684) KS Johansen, BA Woda, D Baiyee, Z Jiang - UMass Memorial Health Care, Worcester, MA 90 Utility of a Panel of Immunohistochemical Markers in Differentiating Prostate Carcinoma from Benign Seminal Vesicle Epithelium: A Study of 31 Radical Prostatectomy Cases with Seminal Vesicle Invasion (623) MN de Peralta-Venturina, TC Killeen, HF Chhatriwala, SH Merchant, RK Malhotra, MB Amin - William Beaumont Hospital, Royal Oak, MI; Univ of Chicago, Chicago, IL; University of New Mexico, Albuquerque, NM 91 Diagnostic Utility of Cytokeratin 5/6 in Differentiation of Benign from Malignant Glands on Prostate Needle Biopsies (785) MP Vacanti, Z Jiang, L Kordunsky, C Li - University of Massachusetts Medical School, Worcester, MA 92 Detection of Small Focal Prostate Cancer by a-Methylacyl Co-A Racemase/P504S Immunohistochemistry in Previously Negative Biopsies (603) BM Carswell, C Li, X Wang, BA Woda, Z Jiang - University of Massachusetts, Worcester, MA 93 A Sensitivity of P504S / a-Methylacyl-CoA Racemase (AMACR) Immunohistochemistry for the Detection of Prostate Carcinoma on Storage Needle Biopsies (786) VK Vanguri, X Wang, BA Woda, Z Jiang - University of Massachusetts Medical School, Worcester, MA; Brigham and Women's hospital, Boston, MA 94 p63/AMACR Immunohistochemical Antibody Cocktail Staining of De-Stained Prostate Needle Biopsy Tissue Sections (661) O Hameed, PA Humphrey - Washington University School of Medicine, St. Louis, MO 95 Quantitative Analysis of Alpha-Methylacyl CoA Racemase (AMACR) and Fatty Acid Synthase (FAS) Co-Expression in Localized Prostate Cancer (638) JA Elvin, TA Bismar, JT Wei, AM Chinnaiyan, M Loda, MA Rubin - Brigham & Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; University of Michigan, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA 96 Immunohistochemical Expression of Alpha-Methylacyl-CoA Racemase (AMACR) in Ductal Adenocarcinoma of the Prostate (604) JF Catroppo, MW Datta, AA Kajdacsy-Balla, FA Monzon-Bordonaba, R Dhir, AV Parwani - University of Pittsburgh Medical Center, Pittsburgh, PA; University of Milwaukee, Milwaukee, WI 97 Comparison of Utility of Polyclonal and Monoclonal Antibody to alpha Methyl Acyl Co A Racemase (AMACR) in Work-Up of Prostate Cancer (693) LP Kunju, A Chinnaiyan, RB Shah - University of Michigan, Ann Arbor, MI 98 Expression of alpha Methyl- Acyl-CoA Racemase (AMACR) in Prostatic Carcinomas (PC), High Grade Prostatic Intraepithelial Neoplasia (HGPIN), and Benign Glands (BG) in Japanese People (779) T Tsuzuki, N Maeda - Nagoya Daini Red Cross Hospital, Nagoya, Japan 99 Decreased a-Methylacyl CoA Racemase Expression in Localized Prostate Cancer Is Associated with an Increased Rate of Biochemical Recurrence and Cancer Specific Death (748) MA Rubin, TA Bismar, O Andren, L Mucci, R Kim, R Shen, D Ghosh, JT Wei, AM Chinnaiyan, H-O Adami, PW Kantoff, J-E Johansson - Brigham and Women's Hospital, Boston, MA; Orebro University Hospital, Orebro, Sweden; Harvard School of Public Health, Boston, MA; University of Michigan, Ann Arbor, MI; Karolinska Institute, Stockholm, Sweden; Dana Farber Cancer Institute, Boston, MA 100 Prostatic Adenocarcinoma with Mucinous Components a Clinicopathological and Immunohistochemical Study (749) H Samaratunga, I Brown - Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia 101 MUC1 Expression in Acinar Prostatic Adenocarcinomas (627) R Dhir, AV Parwani, M Acquafondata, L Lourdaraj - University of Pittsburgh, Pittsburgh, PA 102 Regulation of HAI-1 Expression by Androgen and Oncogenic Transformation in the Prostate (646) L Fazli, L Chen, S Hawley, J Lucas, S Falcon, R Etzioni, M Gleave, P Nelson, G Ayala, B Knudsen - UBC, Vancouver, BC, Canada; Fred Hutchinson Cancer Research Center, Seattle, WA; Baylor, Houston, TX 103 Differential Expression and Quantitation of 5-Alpha Reductase (5aR) in Prostate Cancer (612) S Chikkamuniyappa, R McMasters, P Ghosh, I Thompson, R Leach, D Troyer - Univ TX Health Science Center at San Antonio, San Antonio, TX 104 The Non-Steroid Anti-Inflammatory Drug Sulindac Sulfide Induces Apoptosis and Growth Arrest in Prostate Cancer Cells (792) Y Wang, LF Zerbini, A Czebere, LA Libermann - Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 105 Upregulated Expression of Androgen Receptor (AR) Specific Transcription Corepressors in Prostate Cancer (808) XM Zhang, J Chiu, XT Kong, J Melamed, C Twiss, P Lee - New York University School of Medicine, New York, NY; Walter Reed Medical Center; 106 Benign Prostatic Hyperplasia: Towards the Development of a Clinically Relevant Molecular Signature (625) A Descazeaud, B Laxman, C Creighton, S Setlur, MD Hofer, R Beroukhim, A De La Taille, AM Chinnaiyan, MA Rubin - Brigham and Women's Hospital, Boston; Boston; University of Michigan, Ann Arbor; Boston; CHU Henri Mondor, Assistance Publique des Hopitaux de Paris, Creteil, France 107 Loss of Tumor Suppressor Gene Expression in Normal Prostate Tissue Adjacent to Cancer (662) C Haqq, R LI, H Dai, M Sayeeduddin, T Thompson, G Ayala - UCSF Comprehensive Cancer Center, San Francisco, CA; Baylor College of Medicine, Houston, TX 108 Differential Protein Expression in Anatomical Zones of the Prostate (702) H Lexander, B Franzen, D Hirschberg, S Becker, M Hellström, T Bergman, H Jörnvall, G Auer, L Egevad - Karolinska Institute, Stockholm, Sweden; Astra-Zeneca R&D, Södertälje, Sweden 109 Direct In Situ Analysis of Telomere Lengths in Primary Tumors and Corresponding Local and Distant Metastases Obtained Via Rapid Autopsy (717) AK Meeker, GS Bova, JL Hicks, AM De Marzo - Johns Hopkins University School of Medicine, Baltimore, MD 110 Androgen Receptor CAG Tract Heterogeneity in Benign and Malignant Prostatic Glands (760) K Sircar, M Alam-Fahmy, A Aprikian, L Beitel, B Gottlieb, M Trifiro, C Alvarado - McGill University Health Center, Montreal, QC, Canada; Jewish General Hospital, Montreal, QC, Canada 111 Allelotyping of Clinical and Pre-Clinical Prostatic Carcinomas (765) H Takahashi, W Lu, M Nakano, M Furusato, H Hano - Jikei University School of Medicine., Nishishinbashi, Minato-ku Tokyo, Japan 112 PCA3 DD3 Gene Expression Is a Marker of Prostate Cancer (768) B Tetu, G Beaudry, G Beaudry, L Piche, C Chypre, Y Fradet - CHUQ-Hotel-Dieu de Quebec, Laval University, Quebec, QC, Canada; DiagnoCure Inc, Quebec, QC, Canada; CHUQ-Hotel-Dieu de Quebec, Laval University, Quebec, QC, Canada 113 Gene Expression Profiles Using Formalin Fixed, Paraffin-Embedded Benign and Prostatic Carcinoma Tissues (793) J Wang-Rodriguez, T Downs, M Bibikova, E Chudin, J Modder, M Kostelec, A Arsanjani, J-B Fan University of California, San Diego, San Diego, CA; Illumina, Inc., San Diego, CA 114 Intratumoral Vascularity in Transurethral Resection Predicts Bladder Carcinoma Metastasis (690) SH Khayyata, RS Singh, R Ali-Fehmi, W Sakr, D Grignon, M Che - Wayne State University, Detroit, MI 115 Endoglin (CD105) and Vascular Endothelial Growth Factor (VEGF) as Prognostic Markers in Prostatic Adenocarcinoma (637) YM EL-Gohary, RS Saad, M Tung, PR Olson, JK Cohen, R Miller, YL Liu, JF Silverman - Allegheny General Hospital, Pittsburgh, PA 116 Microvessel Density and Regulators of Angiogenesis in Prostate Tissue (781) O Tulunay, G Kaygusuz, S Baltaci, O Gogus - Medical School of Ankara University, Ankara, Turkey 117 Immunohistochemical Detection of VEGF in Prostate Cancer (631) JE Dotto, M Healy, W Li, J Concato, D Jain - Yale New Haven Hospital, New Haven, CT; West Haven VA Medical Center, West Haven, CT; Cambridge, MA